Recover Investment Losses: Class Action Initiated Against ARS Pharmaceuticals, Inc. (SPRY)
Levi & Korsinsky, LLP announced a securities class action against ARS Pharmaceuticals (NASDAQ: SPRY) on behalf of investors who purchased SPRY securities between March 9, 2026 and June 24, 2026. The complaint alleges defendants made overly positive but materially false and misleading statements about the expected timeline for expanded CVS Caremark insurance coverage of neffy. ARS disclosed on June 24, 2026 that expanded coverage was not granted by the guided July 1, 2026 deadline and that CVS Caremark deferred its decision to January 2027; the stock fell over 23.9% the next day, from $10.54 to $8.02.
Key figures
- Class period
- March 9, 2026 to June 24, 2026
- One day decline pct
- 23.9%
- Stock price jun24 close
- 10.54
- Stock price jun25 close
- 8.02
- Guided coverage deadline
- July 1, 2026
- Coverage decision deferred to
- January 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.